Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa

About this update from Evofem Biosciences, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":857,"height":242,"url":"https://media.zenfs.com/en/business-wire.com/f411491e68dd8d7a96b876f67b9fd350"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0iIFe0hKh9hoV.apwzi2yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3MQ--/https://media.zenfs.com/en/business-wire.com/f411491e68dd8d7a96b876f67b9fd350","width":857,"height":242},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ImETOTyaP.hGtM7_yuvfoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3MTQ7aD00ODQ-/https://media.zenfs.com/en/business-wire.com/f411491e68dd8d7a96b876f67b9fd350","width":857,"height":242}},"lazy":false},{"type":"text","content":"— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, April 27, 2026--(BUSINESS WIRE)--Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory).","length":413,"tagName":"p"},{"type":"text","content":"SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in females 12 years of age and older and to treat Trichomoniasis (Trich), a common sexually transmitted infection (STI), in people 12 years of age and older.","length":270,"tagName":"p"},{"type":"text","content":""Women everywhere deserve access to effective drugs that treat common sexual health conditions with simple, patient-friendly dosing regimens. We are delighted that Clovis Davis will distribute SOLOSEC—Evofem’s single-dose oral treatment for BV and Trich—in Africa, greatly increasing its global reach," said Saundra Pelletier, Chief Executive Officer of Evofem.","length":371,"tagName":"p"},{"type":"text","content":""We believe SOLOSEC will be well received among healthcare providers and patients in our target markets because it delivers a complete treatment for BV and Trich with just one oral dose, enabling patients to quickly resu...

More updates from Evofem Biosciences, Inc.